A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT06427941 · readout in 650 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

392estimated

Sites

Countries

Brazil, China, France +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-07-23

actual

When the study began enrolling

Primary completion

2028-05-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-05-30

estimated

The whole study's end, after follow-up

First posted

2024-05-24

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metastatic Hepatocellular Carcinoma
Local Advanced Hepatocellular Carcinoma
Alpha-fetoprotein (AFP)-Producing Gastric Cancer
Extragonadal Yolk Sac Tumors
Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Interventions

Drug: BGB-B2033
Drug: Tislelizumab
Drug: Bevacizumab

Primary outcomes

what the primary-completion date above is the date OF

Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured Up to approximately 2 years

Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033

measured Up to approximately 2 years

Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033

measured Up to approximately 2 years

Part C and D: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)

measured Up to approximately 2 years

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed